Liraglutide stimulates insulin secretion and suppresses glucagon secretion in a glucose-dependent manner.1,2
Victoza is administered once daily; liraglutide has a 24 hour duration of action and is effective at lowering fasting and post-prandial blood glucose.1
In a double-blind randomised study, liraglutide in combination with metformin produced significantly greater reductions in HbA1c compared to metformin alone. In addition, significant weight loss was seen in the liraglutide + metformin group compared to the glimepiride + metformin group.3
In another study, the addition of liraglutide to metformin and a glitazone resulted in a significant decrease in mean systolic blood pressure compared to placebo.4 Liraglutide has also been shown to produce an increase in the insulin production of remaining beta cells.2
Liraglutide appears to be generally well tolerated. There was an increase in minor, transient gastrointestinal side effects. No episodes of major hypoglycaemia were observed with liraglutide in combination with metformin with or without a glitazone.4 Hypoglycaemia was common and very common when liraglutide was used in combination with a sulphonylurea. Major hypoglycaemia has primarily been observed when combined with a sulphonylurea.1
- Victoza Summary of product characteristics, 2009.
- Chang A, Jakobsen G, Sturis J et al. The GLP-1 derivative NN2211 restores ß-cell sensitivity to glucose in type 2 diabetic patients after a single dose. Diabetes 2003: 52;1786-1791.
- Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32(1): 84-90.
- Zinman B, Gerich J, Buse J et al. Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus. Diabetes Care 2009; 32(7): 1224-30.
Further information: Novo Nordisk